Compare ALVO & OMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALVO | OMCL |
|---|---|---|
| Founded | 2013 | 1992 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Manufacturing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2021 | 2000 |
| Metric | ALVO | OMCL |
|---|---|---|
| Price | $4.29 | $34.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $7.50 | ★ $57.43 |
| AVG Volume (30 Days) | ★ 904.9K | 558.7K |
| Earning Date | 11-11-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.01 |
| Revenue | N/A | ★ $787,309,000.00 |
| Revenue This Year | $10.60 | $3.69 |
| Revenue Next Year | $22.47 | $0.92 |
| P/E Ratio | ★ $18.20 | $35.09 |
| Revenue Growth | N/A | ★ 9.93 |
| 52 Week Low | $2.94 | $31.75 |
| 52 Week High | $6.53 | $51.84 |
| Indicator | ALVO | OMCL |
|---|---|---|
| Relative Strength Index (RSI) | 39.19 | 42.43 |
| Support Level | $3.10 | $32.11 |
| Resistance Level | $4.59 | $36.63 |
| Average True Range (ATR) | 0.29 | 1.67 |
| MACD | -0.02 | -0.35 |
| Stochastic Oscillator | 16.48 | 4.85 |
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.